terça-feira, 6 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· June 2, 2026

Phison Collaborates with Intel to Bring Larger Local AI Workloads to Intel AI PC Platforms

View original at finance.yahoo.com
Phison Collaborates with Intel to Bring Larger Local AI Workloads to Intel AI PC Platforms Phison and Intel collaborate to bring larger local AI workloads to Intel AI PC Platforms Phison's Pascari aiDAPTIV™ removes local memory constraints on client PCs, enabling larger MoE AI models and agentic AI applications TAIPEI,…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI PCs are evolving into platforms for more sophisticated local AI workloads, and aiDAPTIV helps expand available memory for AI workloads on Intel AI PC platforms, allowing OEMs, developers and end users to run more capable AI applications locally while maintaining privacy and infrastructure efficiency.

    60% confidence
  • Phison and Intel are working to support ISV evaluations, technical demonstrations and optimized workloads for public performance claims.

    60% confidence
  • In Phison testing, aiDAPTIV enabled a 26B-parameter model to run on a system with 16GB of DRAM, compared with 32GB of DRAM required without aiDAPTIV in the same test environment.

    60% confidence
  • aiDAPTIV addresses memory constraints by extending effective AI working memory across system DRAM and high-performance, extreme-endurance NAND flash, reducing DRAM required for certain local AI workloads and supporting runtime features such as KV cache reuse.

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com